Drug development timelines are brutal. Regulatory filings run thousands of pages. Clinical data volumes climb while headcount stays flat. IT infrastructure stopped being a support function and became an operational bottleneck (or an advantage) depending on how it’s managed. This article covers what managed IT solutions for life sciences deliver in practice, what’s moving technically heading into 2026, and where companies tend to get the provider selection wrong.

The Market Context

Pharma IT used to mean keeping SAP alive and managing license renewals. That’s not the job anymore. Roche, Novartis, AstraZeneca — companies at that scale now run serious digital programs, from LIMS to real-world evidence platforms to decentralized trial tooling. Mid-size manufacturers face the same regulatory demands with a fraction of the budget. That gap is part of why the managed services market here keeps growing.

IT solutions for life sciences have stretched well past basic infrastructure. The stack now includes cloud architecture, eCTD submission management, computer system validation, pharmacovigilance platforms — things that didn’t traditionally sit inside IT budgets. For a practical breakdown of what end-to-end support looks like in this sector, more information is available at https://dxc.com/industries/life-sciences-solutions, where DXC Technology describes its approach to regulatory submissions, pharmacovigilance management, and clinical trial transformation.

The regulatory side keeps getting more complicated. FDA published a draft guidance in January 2025 with a seven-step risk framework for evaluating AI in regulated drug development. The EU AI Act classifies a subset of medical AI as high-risk — documentation and oversight requirements that don’t exist elsewhere. Deloitte found over 60% of life sciences executives flagging generative AI and digital transformation as active priorities. Budget allocation, not trend-watching.

What Managed IT Actually Is in This Context

In life sciences, managed IT means a provider taking SLA-backed accountability for the full stack — availability, security, compliance, performance. The compliance piece is what separates this sector from everything else. Audit-readiness through software updates, configuration changes, new regulatory guidance. Not just keeping the lights on.

Managed IT solutions for life sciences differ from generic outsourcing in one way: domain knowledge. Pharma systems require understanding CAPA processes, pharmacovigilance workflows, GxP audit logic, and computer system validation. Not skills that transfer from retail or banking. A provider that needs things explained during FDA inspection prep isn’t the right provider.

What full-scope packages typically cover:

• Cloud infrastructure (AWS, Azure, Google Cloud) with data residency controls
• Platform support across Veeva Vault, SAP S/4HANA Life Sciences, IQVIA systems, LIMS
• Computer System Validation (CSV) and IQ/OQ/PQ qualification
• Pharmacovigilance and ADR reporting
• eCTD submissions to FDA, EMA, and other agencies
• Cybersecurity and incident response (ISO 27001)
• Ongoing 21 CFR Part 11 and Annex 11 compliance monitoring
• License management

A system outage mid-submission to FDA or during a Phase III trial isn’t a helpdesk situation. The financial exposure runs into tens of millions, sometimes more if it triggers regulatory scrutiny. That’s the actual risk context these SLAs need to address.

Where the Gains Show Up

DXC documented a case where a life sciences client saved roughly $15 million renegotiating one software agreement — usage analytics showed the gap between consumption and licensing. Another case: $2.75 million in duplicate subscriptions cut after a merger. Neither is hypothetical.

Compliance tracking is where managed IT solutions for life sciences add structural value. AI tools are spreading into GxP-regulated processes, and FDA requires documented life cycle management for every AI model in regulated use. Annual manual audits can’t sustain that. Automated continuous monitoring can. That’s a structural shift, not just an upgrade.

eCTD submission optimization and GenAI-assisted document drafting cut preparation time and reduce regulatory back-and-forth. Less time answering information requests means faster review cycles.

Ransomware against a pharma MES or a clinical trial database compounds operational damage with regulatory fallout. Precedence Research puts healthcare and life sciences as the fastest-growing segment in AI-driven security compliance — and the attack trends support that.

What’s Actually Moving Technically

GenAI and Agentic AI

Generative AI got into life sciences through the documentation problem. Regulatory submissions run thousands of pages with rigid CTD formatting. Production use cases already include GenAI drafting clinical module sections, automating RTQ responses, and flagging guideline changes in near real time.

DXC built DXC Xponential for enterprise AI scaling — five layers covering Insight, Accelerators, Automation, Approach, and Process. In life sciences this translates to ClinicalWorks for pharmacovigilance and ADR reporting, AI-assisted patient matching, and automated eCTD submissions. DXC cites time-to-value improvements of up to 70%.

IQVIA is running active tests with agentic AI for compliance monitoring and manufacturing deviation detection — systems that handle multi-step task chains and leave a full audit trail. FDA’s 2025 draft guidance was explicit: AI in GxP isn’t validated once. Life cycle evaluation, model drift monitoring, and ALCOA+ documentation are ongoing requirements.

Cloud and Hybrid Infrastructure

Cloud adoption moved slowly in life sciences for legitimate reasons — data sovereignty and audit trail integrity in shared environments. That’s mostly resolved through hybrid architecture: clinical and manufacturing records on private cloud or on-premise, analytics and ML workloads on AWS or Azure. Roche built its genomics platform on Google Cloud. AstraZeneca has multiple AWS partnerships for digital twin work. Pfizer moved manufacturing execution systems to hybrid mode post-pandemic.

IBM Quantum and Pfizer have run joint molecular simulation work. Quantum contributions to molecular docking are projected around 2028–2030 — factor it into roadmaps, don’t build on it yet.

The Compliance Requirements

Compliance coverage has to come standard with managed IT solutions for life sciences — not assembled later. The minimum stack:

• 21 CFR Part 11 — audit trails, access controls, tamper protection for electronic records
• Annex 11 — EU GMP equivalent, focused on computerized system validation
• EU AI Act — high-risk medical AI requires technical documentation and human oversight mechanisms
• ALCOA+ — eight data integrity attributes across all regulated process data
• GDPR / HIPAA — patient data in clinical and real-world data contexts
• ISO 27001 / NIST — information security management structure
• DORA — EU Digital Operational Resilience Act, now applying to IT providers serving regulated industries

Some companies run AI tools for mock audits — automated evidence collection, simulated inspector questions, gap detection before the real visit. A 483 observation is often a documentation problem, not an operational one.

Choosing a Provider

Not every IT solutions provider for life sciences companies carries the same depth of sector knowledge. Larger enterprise providers have dedicated practices; specialist firms work exclusively in this space. Either way, evaluating an IT solutions provider for life sciences companies comes down to a few concrete criteria.

Domain credibility is the first filter. Can the team explain IQ, OQ, PQ differences unprompted? Do they know what a periodic review in CSV covers? Do they understand why version history belongs in a URS? If those questions produce hesitation, that’s an answer.

Partner ecosystem shows up in practice. The stronger IT solutions provider for life sciences companies typically holds working partnerships with Veeva, SAP, AWS, Azure, and ServiceNow — not license resale relationships, but joint product development. DXC’s life sciences stack, for example, runs on this kind of ecosystem: Dynatrace for monitoring, OpenText for test automation, Azure and AWS for infrastructure.

SLA scope is where contracts get vague. Uptime, incident response time, audit support — all need to be explicit. A submission bottleneck in this sector costs differently than downtime elsewhere.

Most organizations don’t migrate everything at once. A provider that can only work with greenfield environments isn’t useful for most of the market.

What Separates Projects That Work

Map every system and data flow before automating anything. Regulators want evidence the system was understood before it changed.

Change management in validated environments means retraining staff with muscle memory around specific workflows — skip it and compliance risk moves from IT to operations.

Continuous monitoring has become the expectation. FDA guidance, IQVIA’s operational data, and Deloitte’s analysis all land in the same place: periodic reviews are giving way to automated always-on tracking.

AI outputs in regulated contexts are drafts. FDA requires documented human review. That applies regardless of model confidence.

Bottom Line

IT solutions for life sciences have become a core operational dependency. The managed model handles complexity most organizations can’t staff in-house across a dozen regulatory and technical domains. The right managed IT solutions for life sciences setup runs in the background — validated, monitored, audit-ready.

Picking the right IT solutions provider for life sciences companies carries real competitive weight now. EU AI Act timelines are live, FDA’s AI governance expectations are tightening, and the gap between well-governed and poorly-governed infrastructure shows up in submission timelines and inspection outcomes.

Related posts:

Other Imaging Techniques in Dilated Cardiomyopathy Basic Echocardiography in Arrhythmogenic Right Ventricular Cardiomyopathy Early Diagnosis of Sports Injuries: Why Timely Imaging Matters Enhancing Diagnostic Accuracy Through Online Radiology Consultation on Ai PACS Dental Imaging Explained: From Bitewings To Panoramic X-Rays Support Systems That Help Working Nurses Succeed in School

Stay updated, free articles. Join our Telegram channel

Join